A novel approach for systematic delivery of a hydrophobic anti-leukemia agent tamibarotene mediated by nanostructured lipid carrier

Journal of Biomedical Nanotechnology

Volumn 9, Issue 9, 2013, Pages 1586-1593

  Liu, Xin ^a   Wang, Zhonglan ^a   Feng, Ruihua ^a   Hu, Yue ^a   Huang, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia (APL); Biodistribution; In vitro release; Nanostructured lipid carriers (NLC); Pharmacokinetic; Tamibarotene

Indexed keywords

BIODISTRIBUTIONS; IN-VITRO; NANOSTRUCTURED LIPID CARRIER (NLC); PROMYELOCYTIC LEUKEMIA; TAMIBAROTENE;

CRYSTALLINE MATERIALS; DIFFERENTIAL SCANNING CALORIMETRY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; EMULSIFICATION; ENZYME INHIBITION; MAMMALS; PHARMACOKINETICS;

LOADING;

DRUG CARRIER; LIPID; NANOSTRUCTURED LIPID CARRIER; TAMIBAROTENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RETENTION; EMULSION; FEMALE; HIGH TEMPERATURE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PROMYELOCYTIC LEUKEMIA; RETICULOENDOTHELIAL SYSTEM; SUSTAINED RELEASE PREPARATION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; DELAYED-ACTION PREPARATIONS; DIFFUSION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LEUKEMIA; LIPIDS; METABOLIC CLEARANCE RATE; MICE; NANOCAPSULES; ORGAN SPECIFICITY; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION;

EID: 84883333376     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1656     Document Type: Article

References (47)

1. S. Ito, Y. Ishida, T. Oyake, M. Satoh, Y. Aoki, S. Kowata, T. Uchiyama, S. Enomoto, T. Sugawara, H. Numaoka, K. Suzuki, and K. Murai, Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk. Lymphoma. 45, 1783 (2004).
2. C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd, CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J. Clin. Oncol. 17, 293 (1999).
3. M. S. Tallman and J. K. Altman, Curative strategies in acute promyelocytic leukemia. Hematology. Am. Soc. Hematol. Educ. Program. 2008, 391 (2008).
4. Z. Y. Wang and Z. Chen, Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111, 2505 (2008).
5. N. Asou, All-trans retinoic acid in the treatment of acute promyelocytic leukemia. Internal Medicine 46, 91 (2007).
6. E. H. Estey, F. J. Giles, M Beran, S O'Brien, S. A. Pierce, S. H. Faderl, J. E. Corge, and H. M. Kantarjian, Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99, 4222 (2002).
7. M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe, Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 99, 759 (2002).
8. L. Delva, M. Cornic, N. Balitrand, F. Guidez, J. M. Miclea, A. Delmer, F. Teillet, P. Fenaux, S. Castaigne, and L. Degos, Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82, 2175 (1993).
9. T. Tobita, A. Takeshita, K. Kitamura, K. Ohnishi, M. Yanagi, A. Hiraoka, T. Karasuno, M. Takeuchi, S. Miyawaki, R. Ueda, T. Naoe, and R. Ohno, Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90, 967 (1997).
10. T. Sanda, T. Kuwano, S. Nakao, S. Iida, T. Ishida, H. Komatsu, K. Shudo, M. Kuwano, M. Ono, and R. Ueda, Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. Leukemia 19, 901 (2005).
11. H. V. Naina, D Levitt, M Vusirikala, L. D. Anderson, Jr, P. P. Scaglioni, A. Kirk, and R. H. Jr. Collins, Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene. J. Clin. Oncol. 29, e534 (2011).
12. K. Ohnishi, PML-RARa inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int. J. Clin. Oncol. 12, 313 (2007).
13. H. Kagechika, Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr. Med. Chem. 9, 591 (2002).
14. I. Miwako and K. Shudo, Oral administration of synthetic retinoid Am80 inhibits the development of type 1 diabetes in non-obese diabetic (NOD) mice. Biol. Pharm. Bull. 32, 157 (2009).
15. M. Takeuchi, T. Yano, E. Omoto, K. Takahashi, M. Kibata, K. Shudo, R. Ueda, R. Ohno, and M. Harda, Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid. Br. J. Haematol. 97, 137 (1997).
16. Y. Kimura and K. Oyashiki, Evaluation of the new drug by the clinician. Tamibarotene. Clinical Practice 24, 991 (2005).
17. Adis International Limited, Tamibarotene: AM 80, retinobenzoic acid, Tamibaro. Drugs R. D. 5, 359 (2004).
18. M. Sugitani, R. Abe, N. Ikarashi, K. Ito, H. Muratake, K. Shudo, and K. Sugiyama, Disposition of a new tamibarotene prodrug in mice. Biol. Pharm. Bull. 32, 1997 (2009).
19. M. Takeuchi, T. Yano, E. Omoto, K. Takahashi, M. Kibata, K. Shudo, M. Harda, R. Uedad, and R. Ohno, Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: Clinical experience with a new synthetic retinoid, Am-80. Leuk. Lymphoma. 31, 441 (1998).
20. C. Yuan, Y. S. Zhang, Y. N. Cheng, X. Xue, W. F. Xu, and X. J. Qu, A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene. Leuk. Lymphoma 53, 295 (2012).
21. M. Yokosawa, Y. Sonoda, S. Sugiyama, R. Saito, Y. Yamashita, M. Nishihara, T. Sstoh, T. Kumabe, M. Yokoyama, and T. Tominaga, Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. Tohoku. J. Exp. Med. 221, 257 (2010).
22. C. Holvoet, Y. Vander Heyden, G. Lories, and J. Plaizier- Vercammen, Preparation and evaluation of paclitaxel-containing liposomes. Pharmazie 62, 126 (2007).
23. L. Wang, Z. Liu, D. Liu, C. Liu, Z. Juan, and N. Zhang, Docetaxelloaded- lipid-based-nanosuspensions (DTX-LNS): Preparation, pharmacokinetics, tissue distribution and antitumor activity. Int. J. Pharm. 413, 194 (2011).
24. M. Üner and G. Yener, Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomedicine 2, 289 (2007).
25. M. D. Joshi and R. H. Muller, Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 161 (2009).
26. R. H. Muller, R. Shegokar, and M. K. Cornelia, 20 years of lipid nanoparticles (SLN and NLC): Present state of development and industrial applications. Curr. Drug. Discov. Technol. 8, 207 (2011).
27. V. Jenning and S. H. Gohla, Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul. 18, 149 (2001).
28. R. H. Müller, M. Radtke, and S. A. Wissing, Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242, 121 (2002).
29. V. Jenning, A. F. Thünemann, and S. H. Gohla, Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199, 167 (2000).
30. R. H. Muller, S. Maassen, C. Schwarz, and W. Mehnert, Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Control Release 47, 261 (1997).
31. F. Q. Hu, S. P. Jiang, Y. Z. Du, H. Yuan, Y. Q. Ye, and S. Zeng, Preparation and characteristics of monostearin nanostructured lipid carriers. Int. J. Pharm. 314, 83 (2006).
32. Q. Luo, J. Zhao, X. Zhang, and W. Pan, Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int. J. Pharm. 403, 185 (2011).
33. D. Liu, Z. Liu, L. Wang, C. Zhang, and N. Zhang, Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloid Surface B 85, 262 (2011).
34. C. R. Yang, X. L. Zhao, H. Y. Hu, K. X. Li, X. Sun, L. Li, and D. W. Chen, Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers. Chem. Pharm. Bull (Tokyo). 58, 656 (2010).
35. Y. C. Kuo and J. F. Chung, Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Colloid Surface. B. 83, 299 (2011).
36. L. J. Jia, D. R. Zhang, Z. Y. Li, C. X. Duan, Y. C. Wang, F. F. Feng, F. H. Wang, Y. Liu, and Q. Zhang, Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloid Surface B 80, 213 (2010).
37. P. Zhang, G. X. Ling, X. L. Pan, S. Sun, T. H. Zhang, X. H. Pu, S. L. Yin, and Z. G. He, Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine: NBM 8, 185 (2012).
38. X. Xu, C. Zhao, H. Yang, Y. Jian, Z. Zhang, and Y. Huang, Antiinflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv. 18, 485 (2011).
39. M. Grassi, D. Voinovich, E. Franceschinis, B. Perissutti, and J. Filipovic-Grcic, Theoretical and experimental study on theophylline release from stearic acid cylindrical delivery systems. J. Control Release 92, 275 (2003).
40. K. Manjunath and V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Release 107, 215 (2005).
41. G. H. Huang, N. Zhang, X. L. Bi, and M. J. Dou, Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity. Int. J. Pharm. 355, 314 (2008).
42. K. Manjunath and V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Release 107, 215 (2005).
43. J. M. Lauweryns and J. H. Baert, Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 115, 625 (1977).
44. W. Wu, Y. Wang, and L. Que, Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 63, 288 (2006).
45. I. Miwako and H. Kagechika, Tamibarotene. Drugs Today (Barc). 43, 563 (2007).
46. A. Sparreboom, J. V. Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. F. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. V. Tellingen, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94, 2031 (1997).
47. Data on File, Pharmaceuticals and Medical Devices Agency of Japan.